BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18045726)

  • 21. Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate.
    Takeuchi T; Kosuge M; Tadokoro A; Sugiura Y; Nishi M; Kawata M; Sakai N; Matile S; Futaki S
    ACS Chem Biol; 2006 Jun; 1(5):299-303. PubMed ID: 17163758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-penetrating peptides in drug development: enabling intracellular targets.
    Chen L; Harrison SD
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):821-5. PubMed ID: 17635156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides.
    Meade BR; Dowdy SF
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):134-40. PubMed ID: 17451840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs.
    Nguyen J; Xie X; Neu M; Dumitrascu R; Reul R; Sitterberg J; Bakowsky U; Schermuly R; Fink L; Schmehl T; Gessler T; Seeger W; Kissel T
    J Gene Med; 2008 Nov; 10(11):1236-46. PubMed ID: 18780309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral biodrug delivery using cell-penetrating peptide.
    Khafagy el-S; Morishita M
    Adv Drug Deliv Rev; 2012 May; 64(6):531-9. PubMed ID: 22245080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling.
    Kilk K; Mahlapuu R; Soomets U; Langel U
    Toxicology; 2009 Nov; 265(3):87-95. PubMed ID: 19799958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein delivery by the cell-penetrating peptide YTA2.
    Myrberg H; Lindgren M; Langel U
    Bioconjug Chem; 2007; 18(1):170-4. PubMed ID: 17226970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif.
    Daniels DS; Schepartz A
    J Am Chem Soc; 2007 Nov; 129(47):14578-9. PubMed ID: 17983240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of cell-penetrating peptides for cargo delivery.
    Pooga M; Langel U
    Methods Mol Biol; 2005; 298():77-89. PubMed ID: 16044541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates.
    Eiríksdóttir E; Mäger I; Lehto T; El Andaloussi S; Langel U
    Bioconjug Chem; 2010 Sep; 21(9):1662-72. PubMed ID: 20684543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006.
    Fischer PM
    Med Res Rev; 2007 Nov; 27(6):755-95. PubMed ID: 17019680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.
    Endoh T; Ohtsuki T
    Adv Drug Deliv Rev; 2009 Jul; 61(9):704-9. PubMed ID: 19383521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Potential of cell penetrating peptides for cell drug delivery].
    Poillot C; De Waard M
    Med Sci (Paris); 2011 May; 27(5):527-34. PubMed ID: 21609675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of amphipathic carrier peptides with membrane components in relation with their ability to deliver therapeutics.
    Deshayes S; Morris MC; Divita G; Heitz F
    J Pept Sci; 2006 Dec; 12(12):758-65. PubMed ID: 17131287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans.
    Ziegler A
    Adv Drug Deliv Rev; 2008 Mar; 60(4-5):580-97. PubMed ID: 18045730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in cell-penetrating, non-peptide molecular carriers.
    Chung SK; Maiti KK; Lee WS
    Int J Pharm; 2008 Apr; 354(1-2):16-22. PubMed ID: 17890027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides.
    Nakase I; Takeuchi T; Tanaka G; Futaki S
    Adv Drug Deliv Rev; 2008 Mar; 60(4-5):598-607. PubMed ID: 18045727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studying the uptake of cell-penetrating peptides.
    Holm T; Johansson H; Lundberg P; Pooga M; Lindgren M; Langel U
    Nat Protoc; 2006; 1(2):1001-5. PubMed ID: 17406337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemically modified cell-penetrating peptides for the delivery of nucleic acids.
    Mäe M; Andaloussi SE; Lehto T; Langel U
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1195-205. PubMed ID: 19831582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides.
    Hodoniczky J; Sims CG; Best WM; Bentel JM; Wilce JA
    Biopolymers; 2008; 90(5):595-603. PubMed ID: 18351583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.